LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A | Dasatinib | 10 | uM | LJP5 | 1 | D01 | 72 | hr | 513 | 294 | 10254 | 0.0287 | -0.1211 |
| MCF 10A | CGP60474 | 10 | uM | LJP6 | 2 | G01 | 72 | hr | 513 | 298 | 10386 | 0.0287 | -0.1178 |
| MCF 10A | Withaferin A | 10 | uM | LJP6 | 2 | G13 | 72 | hr | 513 | 301 | 10386 | 0.0290 | -0.1158 |
| MCF 10A | Dasatinib | 3.33 | uM | LJP5 | 1 | D02 | 72 | hr | 513 | 303 | 10254 | 0.0295 | -0.1149 |
| MCF 10A | Buparlisib | 10 | uM | LJP5 | 2 | H01 | 72 | hr | 513 | 307 | 10349 | 0.0297 | -0.1119 |
| MCF 10A | GSK1059615 | 10 | uM | LJP5 | 2 | E01 | 72 | hr | 513 | 312 | 10349 | 0.0301 | -0.1086 |
| MCF 10A | Dasatinib | 10 | uM | LJP5 | 2 | D01 | 72 | hr | 513 | 313 | 10349 | 0.0302 | -0.1079 |
| MCF 10A | Dasatinib | 3.33 | uM | LJP6 | 1 | I02 | 72 | hr | 513 | 320 | 10537 | 0.0304 | -0.1028 |
| MCF 10A | Geldanamycin | 10 | uM | LJP5 | 1 | O01 | 72 | hr | 513 | 315 | 10254 | 0.0307 | -0.1069 |
| MCF 10A | QL-X-138 | 10 | uM | LJP6 | 1 | F19 | 72 | hr | 513 | 326 | 10537 | 0.0309 | -0.0989 |
| MCF 10A | Buparlisib | 3.33 | uM | LJP5 | 1 | H02 | 72 | hr | 513 | 318 | 10254 | 0.0310 | -0.1049 |
| MCF 10A | Dasatinib | 3.33 | uM | LJP5 | 2 | D02 | 72 | hr | 513 | 324 | 10349 | 0.0313 | -0.1008 |
| MCF 10A | CGP60474 | 3.33 | uM | LJP6 | 1 | G02 | 72 | hr | 513 | 330 | 10537 | 0.0313 | -0.0964 |
| MCF 10A | Geldanamycin | 3.33 | uM | LJP5 | 2 | O02 | 72 | hr | 513 | 329 | 10349 | 0.0318 | -0.0976 |
| MCF 10A | AZD7762 | 10 | uM | LJP6 | 3 | L01 | 72 | hr | 513 | 334 | 10494 | 0.0318 | -0.0940 |
| MCF 10A | CGP60474 | 10 | uM | LJP6 | 1 | G01 | 72 | hr | 513 | 338 | 10537 | 0.0321 | -0.0914 |
| MCF 10A | GSK1059615 | 10 | uM | LJP6 | 1 | C01 | 72 | hr | 513 | 340 | 10537 | 0.0323 | -0.0902 |
| MCF 10A | Geldanamycin | 10 | uM | LJP5 | 2 | O01 | 72 | hr | 513 | 335 | 10349 | 0.0324 | -0.0938 |
| MCF 10A | Dasatinib | 3.33 | uM | LJP6 | 3 | I02 | 72 | hr | 513 | 341 | 10494 | 0.0325 | -0.0897 |
| MCF 10A | Buparlisib | 10 | uM | LJP5 | 3 | H01 | 72 | hr | 513 | 343 | 10483 | 0.0327 | -0.0885 |
| MCF 10A | A443654 | 10 | uM | LJP6 | 2 | I19 | 72 | hr | 513 | 344 | 10386 | 0.0331 | -0.0881 |
| MCF 10A | A443654 | 3.33 | uM | LJP6 | 1 | I20 | 72 | hr | 513 | 349 | 10537 | 0.0331 | -0.0847 |
| MCF 10A | Canertinib | 10 | uM | LJP6 | 1 | H07 | 72 | hr | 513 | 350 | 10537 | 0.0332 | -0.0841 |
| MCF 10A | GSK1059615 | 10 | uM | LJP6 | 3 | C01 | 72 | hr | 513 | 351 | 10494 | 0.0334 | -0.0836 |
| MCF 10A | AZD7762 | 10 | uM | LJP6 | 1 | L01 | 72 | hr | 513 | 352 | 10537 | 0.0334 | -0.0829 |